 Connection
Joshua Barocas to Opiate Substitution Treatment
This is a "connection" page, showing publications Joshua Barocas has written about Opiate Substitution Treatment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.764 |
|
|
|
-
Guan X, Jurecka C, Padmanabhan P, Yamkovoy K, Christine PJ, Binswanger IA, Glanz JM, Kline DM, Barocas JA. Impact of increased criminal penalties for fentanyl possession on initiation and retention on medications for opioid use disorder in Colorado. Int J Drug Policy. 2025 12; 146:105037.
Score: 0.760
-
Linas BP, Savinkina A, Madushani RWMA, Wang J, Eftekhari Yazdi G, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, Murphy SM, Schackman BR, Chrysanthopoulou SA, White LF, Barocas JA. Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Netw Open. 2021 02 01; 4(2):e2037259.
Score: 0.548
-
Castry M, Tin Y, Feder NM, Lewis N, Chatterjee A, Rudorf M, Samet JH, Beers D, Medley B, Gilbert L, Linas BP, Barocas JA. An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorder. J Subst Use Addict Treat. 2024 Dec; 167:209517.
Score: 0.176
-
Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy. 2019 10; 72:160-168.
Score: 0.122
-
Barbosa C, Chen Q, Sahinkoc M, Zarkin GA, Dowd W, Villani J, Barocas JA, Cerdá M, Chatterjee A, Fareed N, Hyder A, Keyes KM, Larochelle MR, Linas BP, Roberts SM, Schackman BR, Seiber E, Wakeman SE, Knudsen AB, Chhatwal J. Impact of enhanced practices on opioid overdose deaths: A community-based modeling approach. Addiction. 2026 Jul; 121(7):1747-1760.
Score: 0.049
-
Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 09; 117(9):2450-2461.
Score: 0.037
-
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 10; 117(10):2635-2648.
Score: 0.037
-
Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|